4.6 Article

Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial

期刊

JOURNAL OF THROMBOSIS AND HAEMOSTASIS
卷 12, 期 8, 页码 1254-1259

出版社

WILEY
DOI: 10.1111/jth.12613

关键词

anticoagulation; bleeding; D-dimer; international normalized ratio; surgery

资金

  1. Astra-Zeneca
  2. Bayer
  3. Boehringer Ingelheim
  4. Bristol-Myers Squibb/Pfizer
  5. Daiichi Sankyo
  6. Eli Lilly
  7. GlaxoSmithKline
  8. Janssen
  9. Sanofi-Aventis

向作者/读者索取更多资源

Background: There is uncertainty regarding the optimal dosing regimen for the resumption of warfarin after interruption for invasive procedures. Aim: To determine the efficacy and safety of warfarin resumption with loading doses or with the most recent maintenance dose. Methods: Patients receiving warfarin treatment and planned for invasive procedures with an expected hospital stay of <= 1 day were randomized to resume warfarin on the day of the procedure, defined as day 1, with most recent maintenance dose or with 2 initial days of double maintenance dose. Efficacy outcomes were proportion of international normalized ratio (INR) levels >= 2.0 on day 5 (primary outcome) and day 10. Safety outcomes were bleeding and thromboembolic events. In addition, D-dimer levels were analyzed on days 5 and 10 in a subset of the population. Results: There were 49 patients analyzed in each group. INR of >= 2.0 had been achieved by day 5 for 13% in the maintenance-dose group and for 50% in the loading-dose group (relative risk [RR] 0.27, 95% confidence interval [CI] 0.10-0.60) and by day 10 for 68% and 87%, respectively (RR 0.78, 95% CI 0.65-1.00). There were no thromboembolic events, and there was one major bleed before resumption of warfarin and one minor bleed, both in the maintenance-dose group. There was no difference between the groups in the proportion of patients with excessive INRs or elevated D-dimer levels or in the median D-dimer level. Conclusion: Resumption of warfarin after minor-moderately invasive procedures with two loading doses achieves therapeutic INR faster than does only maintenance dose.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据